Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Condition:   Cervical Cancer Interventions:   Biological: Pembrolizumab;   Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Placebo to pembrolizumab Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials